EHouse Global Closes $10,000,000 Equity Financing With International Private Equity Fund

        Print
| Source: EHouse Global Inc

LA JOLLA, Calif., Jan. 24, 2014 (GLOBE NEWSWIRE) -- EHouse Global, Inc. (OTCBB:EHOS), (the "Company") (www.EHouse-Global.com), an specialty nutraceutical company in the $26 Billion dietary supplement industry, would like to announce it has closed a $10,000,000 equity line facility with Dutchess Opportunity Fund, II, LP (or "Dutchess").

Dutchess is a Boston, MA headquartered private equity fund, with several other offices in large financial centers. Dutchess is an investment manager which provides flexible financing solutions for growth-stage and mature public companies. Founded 14 years ago, Dutchess has funded over $200 million in direct investments and over $2 billion in Equity Line Facilities (ELFs).

Douglas Leighton, managing director stated, "We are excited to be working with management and fund them through this structure in order to provide capital for the growth."

Scott Corlett, President and CFO stated, "We are happy to partner with Dutchess on this transaction. Their reputation and experience in this industry is the reason we chose Dutchess."

EHouse is required to file a registration statement with the SEC within 21 days of the signing of this agreement, and, once effective, will enable the Company to sell stock to Dutchess on an ongoing basis which the Company intends to use for general corporate purposes, working capital, inventory and potential acquisitions.

About EHouse Global (EHOS)

EHouse Global is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol EHOS. Headquartered in La Jolla, CA, EHouse Global acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors. For information about EHouse go to www.ehouse-global.com

Through our wholly owned subsidiary NutraLiquids LLC, our launch includes 16 different liquid nutritional products in single serving pouches with some products also available in 30 day supply, 30 ounce bottles. Each product is gluten-free and are loaded with vitamins, nutrients and natural ingredients proven to support each product's unique claim.

From Immunity Support to Weight loss, Omega 3 Heart Health, Detox, Energy, Sleep, Joint Support, Bone Health, Daily Vitamins and even Hangover prevention, we have created a wide variety of hot product segments for the large and growing nutrition industry and are poised for significant growth.

About Dutchess Capital

Dutchess Capital was founded in 1996. Since then, Dutchess has been a market leader and innovator in providing equity finance facilities and other unique financing structures for publicly-traded companies. Dutchess has transacted over $2 billion in ELF commitments and over $200 million in direct investments globally. Dutchess has over 15 years of experience assisting companies as well as the financial wherewithal to fund the company throughout the entire commitment. Dutchess sources worldwide investment opportunities, with offices in Boston, New York, Seoul and Beijing and joint venture partner First Columbus in London.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the ability of the Company to reach its expansion goals and generate exciting new developments. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Investor & Media Contact:
Email: 
Toll Free: 1 (855) 228-7336